Herein, we show that, treating TRPV2+ EC cells with CIS, DOX or PAC, the presence of TRPV2 expression increased CIS cytotoxic effect, suggesting that TRPV2 can influence chemo-sensitivity to this drug. The gene discussed is TRPV2; the disease is in situ carcinoma.